Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?

For an amorphous drug-polymer solid dispersion, a distinctive single T(g) intermediate of the two T(g) values of the two components has been widely considered as an indication of the mixing uniformity, which is critical for the stability of the amorphous drug against crystallization. In this study, two batches of amorphous solid dispersions consisting of BMS-A, a poorly water-soluble drug, and PVP-VA, were made by a twin-screw hot-melt extruder using different processing conditions. Both batches displayed an identical distinctive single T(g) that is consistent with the prediction of Fox equation assuming homogeneous mixing of the two components. Neither DSC nor PXRD detected any drug crystallinity in either batch. However, the two batches exhibited different physical stability against crystallization over time. The application of a Raman mapping method showed that the drug distributed over a much wider concentration range in the less stable solid dispersion. It is therefore experimentally demonstrated that, in the characterization of amorphous solid dispersions, a distinctive single T(g) may not always be a reliable indicator of homogeneity and optimal stability, and more examinations and new techniques may be required other than conventional studies.

[1]  Bruno C. Hancock,et al.  Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures , 1995, Pharmaceutical Research.

[2]  Feng Qian,et al.  Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development. , 2010, Journal of pharmaceutical sciences.

[3]  Simon Bates,et al.  Characterization of amorphous API:Polymer mixtures using X-ray powder diffraction. , 2008, Journal of pharmaceutical sciences.

[4]  A. Serajuddin,et al.  Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.

[5]  C. Angell,et al.  The Glass Transition of Water, Based on Hyperquenching Experiments , 2001, Science.

[6]  Y. Khimyak,et al.  Amorphous drug-PVP dispersions: application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. , 2009, Journal of pharmaceutical sciences.

[7]  G. Van den Mooter,et al.  Review: physical chemistry of solid dispersions , 2009 .

[8]  David S. Jones,et al.  Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions. , 2010, Journal of pharmaceutical sciences.

[9]  L. S. Taylor,et al.  Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. , 2009, Molecular pharmaceutics.

[10]  Lynne S Taylor,et al.  Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. , 2010, Molecular pharmaceutics.

[11]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  Ping Gao,et al.  Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. , 2008, Molecular pharmaceutics.

[13]  T. Fox Influence of Diluent and of Copolymer Composition on the Glass Temperature of a Poly-mer System , 1956 .

[14]  R. T. Berendt,et al.  Solid-state NMR spectroscopy in pharmaceutical research and analysis , 2006 .

[15]  Bruno C. Hancock,et al.  Disordered drug delivery: destiny, dynamics and the Deborah number , 2002, The Journal of pharmacy and pharmacology.

[16]  Sumie Yoshioka,et al.  Miscibility of nifedipine and hydrophilic polymers as measured by (1)H-NMR spin-lattice relaxation. , 2007, Chemical & pharmaceutical bulletin.

[17]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.